39 results on '"Guegan, Jean-Philippe"'
Search Results
2. Deciphering the correlation between metabolic activity through 18F-FDG-PET/CT and immune landscape in soft-tissue sarcomas: an insight from the NEOSARCOMICS study
3. Pembrolizumab combined with low-dose cyclophosphamide and intra-tumoral injection of the toll-like receptor 4 agonist G100 in patients with advanced pretreated soft tissue sarcoma: results from the PEMBROSARC basket study
4. Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma
5. Phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced breast cancer
6. CD95/Fas protects triple negative breast cancer from anti-tumor activity of NK cells
7. Data from Antitumor Effects of PRMT5 Inhibition in Sarcomas
8. Antitumor Effects of PRMT5 Inhibition in Sarcomas
9. Abstract LB224: STC-1010 a new therapeutic vaccine promotes tumor cell death
10. Abstract 5613: Tumor glucose metabolism profiles detected via [18F]-FDG PET/CT correlate with the immune landascape in soft-tissue sarcomas
11. Abstract 4341: Indoleamine 2,3-dioxygenase 1 is highly expressed in tertiary lymphoid structures and associated with improved outcome in patients with advanced non-small cell lung cancer treated with anti-PD1/PDL1 inhibitors
12. Abstract 6767: Cancer-associated fibroblasts promote T-cell exclusion and resistance to immunotherapy in non-small cell lung cancer with tertiary lymphoid structures
13. Abstract 4705: Profiling of immune cell components and soluble factors in ovarian cancer ascites highlights impaired immune environment
14. 141 Indoleamine 2,3 dioxygenase expression predicts response to immune checkpoint blockers in advanced non-small cell lung cancer
15. 135 Identification of super-exhausted T cells: a novel population predictive of response to immunotherapy
16. 1426 Comprehensive analysis of a novel anti-PDL1 resistant sarcoma mouse model
17. Abstract 3937: PRMT5 inhibition suppress soft tissue sarcomas tumorigenicity through the regulation of glucose metabolism
18. Abstract 1251: Low plasma Arginine level is associated with resistance to immune checkpoint blockers in patients with advanced cancer
19. Abstract 622: Development and characterization of a novel anti-PD1 resistant sarcoma mouse model
20. Abstract 2527: Ovarian cancer ascites display altered immune environment featured by enhanced soluble factors and suppressive cellular context
21. Abstract 2578: High regulatory T cells infiltrate within tertiary lymphoid structure restricts response to immune checkpoint blockers in sarcomas
22. Identification of super-exhausted T cells: A novel population predictive of response to immunotherapy.
23. Impact of acetaminophen on the efficacy of immunotherapy in patients with cancer.
24. Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies
25. Regorafenib–avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial
26. Additional file 1 of Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma
27. Additional file 1 of Pembrolizumab combined with low-dose cyclophosphamide and intra-tumoral injection of the toll-like receptor 4 agonist G100 in patients with advanced pretreated soft tissue sarcoma: results from the PEMBROSARC basket study
28. Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives
29. Selectins impair regulatory T cell function and contribute to systemic lupus erythematosus pathogenesis
30. PD1 inhibition in soft-tissue sarcomas with tertiary lymphoid structures: A multicenter phase II trial.
31. Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial
32. Probing the side chain tolerance for inhibitors of the CD95/PLCγ1 interaction
33. Synthesis of peptidomimetics and chemo-biological tools for CD95/PLCγ1 interaction analysis
34. Abstract 934: “GPCR-ome” modulation upon PD1 / PDL1 axis blockade
35. TROP2 expression and response to immune checkpoint inhibition in patients with advanced non-small cell lung cancer.
36. The complexity of ERK1 and ERK2 MAPKs in multiple hepatocyte fate responses
37. The complexity of ERK1 and ERK2 MAPKs in multiple hepatocyte fate responses.
38. 2.27 Differential Gene Expression and Secretory Profiles of Nurse-like Cells Specifically Derived from Chronic Lymphocytic Leukemia Help Decipher New Pathways to Pathogenesis
39. Upregulation of Indoleamine 2,3-Dioxygenase 1 in Tumor Cells and Tertiary Lymphoid Structures is a Hallmark of Inflamed Non-Small Cell Lung Cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.